Cytokinetics CFO sells shares after option exercise
Cytokinetics EVP and CFO Sung Lee reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cytokinetics EVP and CFO Sung Lee reported an exercise-and-sell transaction in company stock. On June 24, 2026, Lee exercised stock options to acquire a total of 38,730 shares of Cytokinetics common stock at strike prices of $48.51 and $44.36 per share, then sold 38,730 shares in an open-market sale at an average price of $82.30 per share. Following the sale, Lee directly owned 63,221 shares of Cytokinetics common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 38,730 shares ($1.36M approx. pre-tax spread)
Exercise and Sale
15 txns
Insider
Lee Sung
Role
EVP, Chief Financial Officer
Sold
38,730 shs ($3.19M)
Approx. gross sale proceeds
$3.19M
Approx. exercise cost
$1.82M
Approx. pre-tax spread
$1.36M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 23,370 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 9,307 | $0.00 | $0.00 |
| Exercise | Incentive Stock Option (Right to Buy) | 2,817 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 1,113 | $0.00 | $0.00 |
| Exercise | Incentive Stock Option (Right to Buy) | 188 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 822 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 1,113 | $0.00 | $0.00 |
| Exercise | Common Stock | 23,370 | $48.51 | $1.13M |
| Exercise | Common Stock | 9,307 | $44.36 | $413K |
| Exercise | Common Stock | 2,817 | $44.36 | $125K |
| Exercise | Common Stock | 1,113 | $48.51 | $54K |
| Exercise | Common Stock | 188 | $44.36 | $8K |
| Exercise | Common Stock | 822 | $44.36 | $36K |
| Exercise | Common Stock | 1,113 | $48.51 | $54K |
| Sale | Common Stock | 38,730 | $82.30 | $3.19M |
Holdings After Transaction:
Incentive Stock Option (Right to Buy) — 6,011 contracts (Direct);
Non-Qualified Stock Option (Right to Buy) — 59,018 contracts (Direct);
Common Stock — 63,221 shares (Direct)
Key Figures
Shares sold: 38,730 shares
Sale price: $82.30 per share
Options exercised: 38,730 shares
+3 more
6 metrics
Shares sold
38,730 shares
Open-market sale of common stock on June 24, 2026 at $82.30
Sale price
$82.30 per share
Average price for 38,730 common shares sold June 24, 2026
Options exercised
38,730 shares
Total underlying common shares from derivative exercises on June 24, 2026
Option strike price 1
$48.51 per share
Exercise price for certain non-qualified stock options
Option strike price 2
$44.36 per share
Exercise price for certain non-qualified and incentive stock options
Shares owned after sale
63,221 shares
Direct holdings of common stock following the June 24, 2026 transactions
Key Terms
open-market sale, Non-Qualified Stock Option (Right to Buy), Incentive Stock Option (Right to Buy), derivative exercise/conversion
4 terms
open-market sale financial
"38,730 shares in an open-market sale at an average price of $82.30 per share"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Non-Qualified Stock Option (Right to Buy) financial
"security_title: "Non-Qualified Stock Option (Right to Buy)" with an exercise price of $48.51"
Incentive Stock Option (Right to Buy) financial
"security_title: "Incentive Stock Option (Right to Buy)" with an exercise price of $44.36"
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for multiple M-coded option transactions"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cytokinetics (CYTK) CFO Sung Lee report in this Form 4?
Sung Lee reported exercising stock options and selling Cytokinetics common shares. On June 24, 2026, he exercised options for 38,730 shares and sold 38,730 shares in an open-market transaction at an average price of $82.30 per share.
What options did Cytokinetics (CYTK) CFO Sung Lee exercise in this filing?
He exercised stock options covering 38,730 underlying shares of Cytokinetics common stock. These included options with exercise prices of $48.51 and $44.36 per share, converting derivative positions into common shares before the reported open-market sale on June 24, 2026.
Were the Cytokinetics (CYTK) CFO’s transactions open-market trades or something else?
The Form 4 shows an open-market sale of 38,730 Cytokinetics shares coded as “S.” The surrounding transactions with code “M” reflect derivative exercises or conversions, where stock options were exercised to acquire common shares before the sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.
